Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

Blood cancer journal·2017

Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression.

Leukemia·2016

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.

Leukemia·2016

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

Leukemia & lymphoma·2016

Heterogeneity of CD5 Membrane Expression on B-Chronic Lymphocytic Leukemia Cells.

Leukemia & lymphoma·2016

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

Leukemia·2015

A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.

Blood·2026

EVIDENCE OF CLL DEVELOPMENT FROM HEMATOPOIETIC PROGENITOR CELLS IN HUMANS.

Blood·2026

Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.

Blood·2026

TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.

Blood·2026

Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.

Blood·2026

STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.

Blood·2026

Triple M Overlap Syndrome: A Rare Complication of Immune Checkpoint Inhibitors.

Cureus·2026

Long-term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia.

HemaSphere·2026

Establishing environmental causes of childhood cancer: a view from the IARC Monographs.

UCL open. Environment·2026

Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed Ldlr-/- mice.

Atherosclerosis plus·2026

Neuro-immune-bone axis in post-traumatic bone regeneration: temporal regulation, dysregulation mechanisms, and therapeutic implications.

Frontiers in immunology·2026

Innate immune signaling-driven myeloid remodeling in cancer: inflammatory amplification, immune suppression, and therapeutic targeting.

Frontiers in immunology·2026

Related Experiment Videos

Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group

Related Concept Videos

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression.

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

Heterogeneity of CD5 Membrane Expression on B-Chronic Lymphocytic Leukemia Cells.

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.

EVIDENCE OF CLL DEVELOPMENT FROM HEMATOPOIETIC PROGENITOR CELLS IN HUMANS.

Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.

TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.

Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.

STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.

Triple M Overlap Syndrome: A Rare Complication of Immune Checkpoint Inhibitors.

Long-term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia.

Establishing environmental causes of childhood cancer: a view from the IARC Monographs.

Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed Ldlr-/- mice.

Neuro-immune-bone axis in post-traumatic bone regeneration: temporal regulation, dysregulation mechanisms, and therapeutic implications.

Innate immune signaling-driven myeloid remodeling in cancer: inflammatory amplification, immune suppression, and therapeutic targeting.

Related Experiment Videos

Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group

Related Concept Videos

Related Articles